<DOC>
	<DOCNO>NCT00030797</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness combination chemotherapy treat patient advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy different schedule irinotecan combination capecitabine first-line therapy , term objective response rate , patient advance metastatic colorectal cancer . - Compare time treatment failure , time progression , overall survival patient treat regimen . - Compare safety profile , term toxicity , regimens patient . - Determine quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord performance status ( 0 vs 1 ) ; disease symptom , include pain , weight loss , loss appetite , malaise , fever unknown origin ( yes v ) ; weight loss past 6 month ( 5 % vs 5 % less ) ; disease-free interval ( 6 month vs 6 month less ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive irinotecan IV 1 hour day 1 , 8 , 15 , 22 , 29 oral capecitabine twice daily day 1-14 22-35 . - Arm II : Patients receive irinotecan IV 1 hour day 1 22 oral capecitabine arm I . Treatment arm repeat every 6 week absence disease progression unacceptable toxicity . Quality life assess baseline , day 1 course , first visit treatment failure . Patients follow every 12 week 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 28-74 patient ( 14-37 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic colorectal cancer Unresectable disease At least 1 bidimensionally measurable lesion At least 2 cm perpendicular diameter No evidence CNS metastases PATIENT CHARACTERISTICS : Age : 18 75 Performance status : 01 Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.25 time ULN Cardiovascular : No clinically significant cardiac disease No congestive heart failure No New York Heart Association class III IV heart disease No symptomatic coronary artery disease No uncontrolled cardiac arrhythmia No myocardial infarction within past year Gastrointestinal : No evidence dysphagia No malabsorption intestinal obstruction would affect absorption excretion study drug No chronic diarrhea Other : No malignancy within past 5 year except adequately treat carcinoma situ cervix localize nonmelanoma skin cancer No psychiatric disability would preclude study compliance No significant medical condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy advance metastatic disease Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 4 week since prior major surgery gastrointestinal tract Other : No concurrent therapy history seizure CNS disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>